ArticleJoint diseases and related surgery2025
Clinical effectiveness of platelet rich fibrin combined with core decompression and grafting in early stage femoral head avascular necrosis.
Article in Joint diseases and related surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Osteogenic effect of platelet-rich fibrin on a bone defect model of long bone in rabbits.Joint diseases and related surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to evaluate the clinical effectiveness of platelet-rich fibrin (PRF) therapy in combination with core decompression (CD) and grafting in patients with femoral head avascular necrosis (AVNFH). PATIENTS AND
methodsBetween February 2015 and February 2020, a total of 63 patients (45 males, 18 females; mean age: 45.8±11.7 years; range, 21 to 65 years) with early-stage AVNFH (Ficat-Arlet Stages I-II) who underwent treatment were retrospectively analyzed. The patients were divided into two groups: those treated with CD and grafting (CD+grafting; n=32) and those receiving additional PRF augmentation (CD+grafting+PRF; n=31). Demographic characteristics, including age, sex, and affected side, were comparable between the groups. Clinical assessments included pre- and postoperative Visual Analog Scale (VAS) for pain, Harris Hip Score (HHS), and Merle d'Aubigné Hip Score.
resultsNo significant differences were observed between the groups preoperatively regarding HHS, Merle d'Aubigné scores, and VAS scores (p>0.05). Postoperatively, the PRF group demonstrated significantly improved outcomes in HHS (83.70±14.30 vs. 65.90±16.72, p=0.001), Merle d'Aubigné Hip Score (15.29±2.78 vs. 11.94±4.31, p=0.001), and VAS (2.06±1.50 vs. 4.69±2.08, p=0.001). Both groups showed significant clinical improvement, but PRF augmentation was associated with superior functional recovery and pain reduction.
conclusionCompared to CD+grafting alone, adding PRF to CD+grafting resulted in more favorable clinical outcomes with minimal complications. These findings suggest that PRF is a promising, minimally invasive adjunct therapy for joint preservation in early-stage AVNFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.